New diabetes pill burns fat while preserving muscle and appetite

A compound being developed in Sweden works through an entirely different mechanism than the injection-based GLP-1 drugs now dominating diabetes treatment—and early evidence suggests it might avoid their most frustrating trade-offs.

The problem with current blockbuster treatments like Ozempic is well-documented by now: they suppress appetite so effectively that people often lose muscle along with fat, and some experience significant gastrointestinal side effects. For many patients, that's a worthwhile exchange. But for others, the muscle loss is a genuine concern—particularly since muscle mass correlates directly with longevity and metabolic health.

Instead of dampening hunger signals between your gut and brain, this new tablet (still unnamed in early development) works directly on muscle cells themselves. It activates metabolic pathways that ramp up fat burning within skeletal tissue, improving blood sugar control and body composition in animal studies without the appetite suppression.

How it works differently

The active ingredient is a specially designed β2 agonist—a class of molecule that's been used in asthma inhalers for decades. The innovation here is in the engineering. Previous β2 agonists had a problematic side effect: they overstimulated the heart. This new version appears to activate the beneficial pathways in muscle while sidestepping that cardiac risk.

A phase I trial involving 48 healthy volunteers and 25 people with type 2 diabetes found the drug was well tolerated in humans. That's the critical first gate—proving safety before moving forward.

"Our results point to a future where we can improve metabolic health without losing muscle mass," says Tore Bengtsson, a professor at Stockholm University's Wenner-Gren Institute who led the research published in Cell. "Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy."

What makes this particularly promising is the mechanism's independence from GLP-1 drugs. Because they work through completely different biological pathways, this tablet could eventually be used alone—which appeals to patients who'd rather swallow a pill than inject weekly—or combined with GLP-1 medications for patients who need more aggressive treatment.

The next phase is a larger clinical trial, planned by Atrogi AB (the company developing the drug), that will test whether these early results hold up in actual patients living with type 2 diabetes or obesity. That's where the real question gets answered: does a lab finding translate to lived experience.

The research involved teams across Sweden, Denmark, and Australia, with funding from the Swedish Research Council and the Novo Nordisk Foundation. Several researchers, including Bengtsson, have financial ties to Atrogi AB—a standard disclosure in early-stage drug development, though worth noting when evaluating the hype.

We're still years away from knowing whether this becomes a meaningful option for patients. But the principle it's testing—targeting metabolism directly rather than appetite—opens a different door in how we think about treating metabolic disease.